CN111989098A - 用于治疗肌肉疾病的化合物和组合物 - Google Patents

用于治疗肌肉疾病的化合物和组合物 Download PDF

Info

Publication number
CN111989098A
CN111989098A CN201980026811.XA CN201980026811A CN111989098A CN 111989098 A CN111989098 A CN 111989098A CN 201980026811 A CN201980026811 A CN 201980026811A CN 111989098 A CN111989098 A CN 111989098A
Authority
CN
China
Prior art keywords
epicatechin
bone
muscle
follistatin
weakening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980026811.XA
Other languages
English (en)
Chinese (zh)
Inventor
G.F.施雷纳
G.塞巴洛斯
S.杜加尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epilim Biological Co ltd
Epirium Bio Inc
Original Assignee
Epilim Biological Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/900,533 external-priority patent/US20180193306A1/en
Application filed by Epilim Biological Co ltd filed Critical Epilim Biological Co ltd
Publication of CN111989098A publication Critical patent/CN111989098A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74Benzo[b]pyrans, hydrogenated in the carbocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980026811.XA 2018-02-20 2019-02-20 用于治疗肌肉疾病的化合物和组合物 Pending CN111989098A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/900,533 US20180193306A1 (en) 2012-03-23 2018-02-20 Compounds and compositions for the treatment of muscular disorders and bone disorders
US15/900,533 2018-02-20
PCT/US2019/018730 WO2019164914A1 (fr) 2018-02-20 2019-02-20 Composés et compositions pour le traitement de troubles musculaires

Publications (1)

Publication Number Publication Date
CN111989098A true CN111989098A (zh) 2020-11-24

Family

ID=67687368

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980026811.XA Pending CN111989098A (zh) 2018-02-20 2019-02-20 用于治疗肌肉疾病的化合物和组合物

Country Status (8)

Country Link
EP (1) EP3755319A4 (fr)
JP (1) JP2021514380A (fr)
CN (1) CN111989098A (fr)
AU (1) AU2019224003A1 (fr)
BR (1) BR112020016923A2 (fr)
CA (1) CA3091892A1 (fr)
IL (1) IL276786A (fr)
WO (1) WO2019164914A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10052316B2 (en) 2011-06-06 2018-08-21 Cardero Therapeutics, Inc. Methods and compositions for treatment of mitochondrial toxicity
US10898465B2 (en) 2016-06-21 2021-01-26 Epirium Bio Inc. Utility of (+) epicatechin and their analogs
WO2024036225A1 (fr) * 2022-08-10 2024-02-15 Epirium Bio Inc. Épicatéchine pour l'inhibition de la toxicité du glutamate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1739498A (zh) * 2005-09-05 2006-03-01 中山大学 (-)-表没食子儿茶素没食子酸酯-钙络合物固体分散体及其制备方法与应用
CN104837369A (zh) * 2012-10-04 2015-08-12 雅培制药有限公司 用于增强EGCg对减缓骨骼肌损失的作用的方法
CN107206040A (zh) * 2014-06-16 2017-09-26 尤尼根公司 用于管理或改进骨病症、软骨病症或二者的组合物和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374966A1 (en) * 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
JP2004161669A (ja) * 2002-11-13 2004-06-10 Ito En Ltd 骨形成促進剤
WO2008155397A2 (fr) * 2007-06-20 2008-12-24 Galapagos N.V. Cibles et composés moléculaires utiles dans le traitement de maladies dégénératives des os et des articulations, et procédés pour les identifier
KR101760758B1 (ko) * 2008-05-14 2017-07-24 애그리컬쳐 빅토리아 서비스 피티와이 엘티디 질병 및 장애를 치료하기 위한 안지오게닌 또는 안지오게닌 아고니스트의 이용
JP2010095474A (ja) * 2008-10-17 2010-04-30 Ito En Ltd カルシウム吸収促進組成物及びカルシウム吸収促進飲食物
KR101096574B1 (ko) * 2008-12-12 2011-12-20 에이치 엘 지노믹스(주) 유럽종 포도의 씨 추출물을 함유하는 골다공증 예방 또는 치료용 약학 조성물
JP2011006355A (ja) * 2009-06-25 2011-01-13 Ito En Ltd 骨密度改善組成物及び飲食物
JP2013051920A (ja) * 2011-09-05 2013-03-21 Ishikawa Prefectural Public Univ Corp 骨密度強化補助食品
EP3884937A1 (fr) * 2012-03-23 2021-09-29 Cardero Therapeutics, Inc. Composés et compositions pour le traitement d'affections musculaires

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1739498A (zh) * 2005-09-05 2006-03-01 中山大学 (-)-表没食子儿茶素没食子酸酯-钙络合物固体分散体及其制备方法与应用
CN104837369A (zh) * 2012-10-04 2015-08-12 雅培制药有限公司 用于增强EGCg对减缓骨骼肌损失的作用的方法
CN107206040A (zh) * 2014-06-16 2017-09-26 尤尼根公司 用于管理或改进骨病症、软骨病症或二者的组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHWAN-LI SHEN. ET AL *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition

Also Published As

Publication number Publication date
WO2019164914A1 (fr) 2019-08-29
BR112020016923A2 (pt) 2020-12-15
EP3755319A1 (fr) 2020-12-30
AU2019224003A1 (en) 2020-10-08
JP2021514380A (ja) 2021-06-10
CA3091892A1 (fr) 2019-08-29
EP3755319A4 (fr) 2021-12-01
IL276786A (en) 2020-10-29

Similar Documents

Publication Publication Date Title
US9901564B2 (en) Compounds and compositions for the treatment of muscular disorders
US11273144B2 (en) Compounds and compositions for the treatment of muscular disorders and bone disorders
CN111989098A (zh) 用于治疗肌肉疾病的化合物和组合物
US20220105117A1 (en) Compositions comprising nicotinamide riboside and a urolithin
Paddon-Jones et al. Role of dietary protein in the sarcopenia of aging
AU2006227949B2 (en) Composition and method for modulating hydrogen ion physiology
US11547736B2 (en) Sauvignon blanc grape seed products for nonalcoholic fatty liver disease
JP2016517438A (ja) 筋肉機能を維持し、改善する方法
EP3897617A1 (fr) Nouveaux composés de polyméthoxyflavone pour la modulation du muscle squelettique, procédés et utilisations de ceux-ci
JP7271016B2 (ja) 骨損失疾患の予防、改善または治療のためのchp(シクロ-ヒスプロ)および副甲状腺ホルモンを含む組成物の用途
US20230255238A2 (en) Compositions and methods using at least one of oleuropein or a metabolite thereof to treat or prevent muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise
KR20090064449A (ko) 신규한 기능식품용 및 약학적 조성물 및 관절 내 연골 분해 또는 연골 손상의 치료, 공동치료 또는 예방을 위한 이의 용도
JP2023547038A (ja) ニコチンアミド及びビタミンb6を含有する組成物、並びにサルコペニア及び虚弱を治療するためにかかる組成物を使用する方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201124